Board of directors
Peter Mørch Eriksen
Chairman of the board
Peter has over 25 years of international experience in the medtech and life science sectors. He is currently focusing on Board leaderships and serves as Chairman of Monsenso A/S and AptaShape ApS. Peter previously held senior roles as CEO of BioPorto A/S and at Medtronic in both the U.S. and Denmark, including Vice President. Peter has a strong track record in driving growth, leading restructurings, and securing funding in complex, technology-driven organizations. With a background in accounting and executive management training, he combines financial expertise with strategic leadership. He is Director of PME Holding ApS and is a member of the Medical Device and Diagnostics Advisory Committee at Cincinnati Children’s Hospital Medical Center.
Born in 1960. Chairman of the board since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 115,669 and 117,500 warrants (Partly owned via PME Holding ApS).
Mats Thorèn
Vice chairman of the board
Mats brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 20 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at Xbrane BioPharma AB, Arcoma AB, Herantis Pharma Oy, BioPorto A/S and C-Rad AB with past board roles at Duocort AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.
Born in 1971. Board member since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 741 and 0 warrants.
Andreas Kjaer
Member of the board
Andreas is an MD, PhD, DMSc, and professor at the University of Copenhagen as well as chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET, PET/MRI and optical probes in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published 700 peer-review articles, and has received multiple prestigious scientific awards throughout the years. Andreas also holds an MBA from Copenhagen Business School.
Born in 1963. Board member since 2018.
Dependent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 2,126,107 (indirectly owned via Life Science ApS) and privately and 141,400 warrants.
Michael Engsig
Member of the board
Michael has extensive experience within the pharmaceutical industry with 20+ years of experience in both foreign capital markets and publicly listed companies. This includes a successful track record in general management, R&D, and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark (DTU) and a graduate diploma in Business Administration (HD) from Copenhagen Business School (CBS).
Born in 1972. Board member since 2023.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Camilla Harder Hartvig
Member of the board
Camilla has 30 years of operational and strategic commercial experience within the worldwide lifescience industry. She has lived abroad for most of her career, only returning to Denmark in 2023. Her most recent roles were as EVP, CCO in Ascendis Pharma in Copenhagen; EVP, CCO in Theramex Ltd based in London and before that SVP for the International region in Alexion Pharmaceuticals based out of Zurich. Camilla has led numerous product launches worldwide, most notably as the VP Global Marketing for AstraZeneca. She has served on boards for more than a decade, in leading companies like Danish Crown and CWorldWide and currently sits on the board of Goddess Gaia Ventures (London), MagCath ApS and Biobridge Partners in Copenhagen. She is a member of the female investor group Angella Invest and is currently enrolled in their Angel and Venture Capital Investor Accelerator Programme. Camilla holds a MBSc in economics and business administration – international marketing and management from CBS, a CEMS MIM from HEC in Paris and board educations from Harvard and INSEAD.
Born in 1969. Board member since 2025.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Peter Mørch Eriksen
Chairman of the board
Peter has over 25 years of international experience in the medtech and life science sectors. He is currently focusing on Board leaderships and serves as Chairman of Monsenso A/S and AptaShape ApS. Peter previously held senior roles as CEO of BioPorto A/S and at Medtronic in both the U.S. and Denmark, including Vice President. Peter has a strong track record in driving growth, leading restructurings, and securing funding in complex, technology-driven organizations. With a background in accounting and executive management training, he combines financial expertise with strategic leadership. He is Director of PME Holding ApS and is a member of the Medical Device and Diagnostics Advisory Committee at Cincinnati Children’s Hospital Medical Center.
Born in 1960. Chairman of the board since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 115,669 and 117,500 warrants (Partly owned via PME Holding ApS).
Mats Thorèn
Vice chairman of the board
Mats brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 20 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at Xbrane BioPharma AB, Arcoma AB, Herantis Pharma Oy, BioPorto A/S and C-Rad AB with past board roles at Duocort AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.
Born in 1971. Board member since 2021.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 741 and 0 warrants.
Andreas Kjaer
Member of the board
Andreas is an MD, PhD, DMSc, and professor at the University of Copenhagen as well as chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET, PET/MRI and optical probes in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published 700 peer-review articles, and has received multiple prestigious scientific awards throughout the years. Andreas also holds an MBA from Copenhagen Business School.
Born in 1963. Board member since 2018.
Dependent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 2,126,107 (indirectly owned via Life Science ApS) and privately and 141,400 warrants.
Michael Engsig
Member of the board
Michael has extensive experience within the pharmaceutical industry with 20+ years of experience in both foreign capital markets and publicly listed companies. This includes a successful track record in general management, R&D, and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark (DTU) and a graduate diploma in Business Administration (HD) from Copenhagen Business School (CBS).
Born in 1972. Board member since 2023.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.
Camilla Harder Hartvig
Member of the board
Camilla has 30 years of operational and strategic commercial experience within the worldwide lifescience industry. She has lived abroad for most of her career, only returning to Denmark in 2023. Her most recent roles were as EVP, CCO in Ascendis Pharma in Copenhagen; EVP, CCO in Theramex Ltd based in London and before that SVP for the International region in Alexion Pharmaceuticals based out of Zurich. Camilla has led numerous product launches worldwide, most notably as the VP Global Marketing for AstraZeneca. She has served on boards for more than a decade, in leading companies like Danish Crown and CWorldWide and currently sits on the board of Goddess Gaia Ventures (London), MagCath ApS and Biobridge Partners in Copenhagen. She is a member of the female investor group Angella Invest and is currently enrolled in their Angel and Venture Capital Investor Accelerator Programme. Camilla holds a MBSc in economics and business administration – international marketing and management from CBS, a CEMS MIM from HEC in Paris and board educations from Harvard and INSEAD.
Born in 1969. Board member since 2025.
Independent in relation to both the Company and executive management as well as larger shareholders.
Number of FluoGuide shares 0 and 7,500 warrants.